ST6GAL2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | ST6GAL2, SIAT2, ST6GalII, ST6 beta-galactoside alpha-2,6-sialyltransferase 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 608472 MGI: 2445190 HomoloGene: 13052 GeneCards: ST6GAL2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
ST6 beta-galactoside alpha-2,6-sialyltransferase 2 is a protein that in humans is encoded by the ST6GAL2 gene.[4]
Function
This locus encodes a sialyltransferase. The encoded type II transmembrane protein catalyzes the transfer of sialic acid from CMP to an oligosaccharide substrate. Polymorphisms at this locus may be associated with variations in risperidone response in schizophrenic patients. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jan 2012].
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000144057 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Entrez Gene: ST6 beta-galactoside alpha-2,6-sialyltransferase 2". Retrieved 2018-08-23.
Further reading
- Krzewinski-Recchi MA, Julien S, Juliant S, Teintenier-Lelièvre M, Samyn-Petit B, Montiel MD, Mir AM, Cerutti M, Harduin-Lepers A, Delannoy P (March 2003). "Identification and functional expression of a second human beta-galactoside alpha2,6-sialyltransferase, ST6Gal II". Eur. J. Biochem. 270 (5): 950–61. doi:10.1046/j.1432-1033.2003.03458.x. PMID 12603328.
- Trynka G, Zhernakova A, Romanos J, Franke L, Hunt KA, Turner G, Bruinenberg M, Heap GA, Platteel M, Ryan AW, de Kovel C, Holmes GK, Howdle PD, Walters JR, Sanders DS, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, Kelleher D, Barisani D, Bardella MT, McManus R, van Heel DA, Wijmenga C (August 2009). "Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling". Gut. 58 (8): 1078–83. doi:10.1136/gut.2008.169052. PMID 19240061. S2CID 17111427.
- Lehoux S, Groux-Degroote S, Cazet A, Dhaenens CM, Maurage CA, Caillet-Boudin ML, Delannoy P, Krzewinski-Recchi MA (January 2010). "Transcriptional regulation of the human ST6GAL2 gene in cerebral cortex and neuronal cells". Glycoconj. J. 27 (1): 99–114. doi:10.1007/s10719-009-9260-y. PMID 19768537. S2CID 21921351.
- Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, Yamanouchi Y, Kinoshita Y, Hashimoto R, Williams HJ, Takeda M, Nakamura J, Nabeshima T, Owen MJ, O'Donovan MC, Honda H, Arinami T, Ozaki N, Iwata N (February 2010). "Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches". Biol. Psychiatry. 67 (3): 263–9. doi:10.1016/j.biopsych.2009.08.030. PMID 19850283. S2CID 25280425.
- Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR (2010). "Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score". Mol. Med. 16 (7–8): 247–53. doi:10.2119/molmed.2009.00159. PMC 2896464. PMID 20379614.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.